{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:54:42Z","timestamp":1790790882122,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jaci.2017.06.032","type":"journal-article","created":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T22:15:11Z","timestamp":1500934511000},"page":"638-649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":233,"title":["Omalizumab treatment in patients with chronic inducible urticaria: A\u00a0systematic review of published evidence"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4121-481X","authenticated-orcid":false,"given":"Marcus","family":"Maurer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randolf","family":"Brehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Hillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Mahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pf\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Staubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Treudler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Wedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Magerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2017.06.032_bib1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","article-title":"The EAACI\/GA2LEN\/EDF\/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update","volume":"69","author":"Zuberbier","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.06.032_bib2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jaip.2016.09.029","article-title":"Prevalence of inducible urticaria in patients with chronic spontaneous urticaria: associated risk factors","volume":"5","author":"Sanchez","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2017.06.032_bib3","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/jdv.14221","article-title":"Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria","volume":"31","author":"S\u00e1nchez-Borges","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2017.06.032_bib4","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/all.12884","article-title":"The definition, diagnostic testing, and management of chronic inducible urticarias\u2014the EAACI\/GA2LEN\/EDF\/UNEV consensus recommendations 2016 update and revision","volume":"71","author":"Magerl","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.06.032_bib5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.anai.2015.06.030","article-title":"Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey","volume":"115","author":"Vietri","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2500\/aap.2014.35.3713","article-title":"Quality of life in patients with urticaria and angioedema: assessing burden of disease","volume":"35","author":"Weldon","year":"2014","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2017.06.032_bib7","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.jaci.2016.05.026","article-title":"Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria","volume":"138","author":"Koch","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2340\/00015555-2150","article-title":"Rupatadine 20 mg and 40 mg are effective in reducing the symptoms of chronic cold urticaria","volume":"96","author":"Abajian","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2017.06.032_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/1744666X.2015.993971","article-title":"Omalizumab for the treatment of chronic urticaria","volume":"11","author":"Zuberbier","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.06.032_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2011.06.010","article-title":"A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria","volume":"128","author":"Saini","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/jid.2014.512","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.06.032_bib14","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/all.12870","article-title":"Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial","volume":"71","author":"Staubach","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.06.032_bib15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","article-title":"Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase","volume":"128","author":"Maurer","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib16","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.7150\/thno.18304","article-title":"Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of Fc\u03b5RI-positive cells in the skin","volume":"7","author":"Metz","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.jaci.2017.06.032_bib17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1398-9995.2010.02472.x","article-title":"Omalizumab\u2014an effective and safe treatment of therapy-resistant chronic spontaneous urticaria","volume":"66","author":"Groffik","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.06.032_bib18","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2015.12.1342","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials","volume":"137","author":"Zhao","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib19","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jaci.2006.04.003","article-title":"Successful treatment of cold-induced urticaria\/anaphylaxis with anti-IgE","volume":"117","author":"Boyce","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib20","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1398-9995.2009.02268.x","article-title":"Effective treatment of refractory severe heat urticaria with omalizumab","volume":"65","author":"Bullerkotte","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.06.032_bib21","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jaci.2010.12.1085","article-title":"Omalizumab is effective in nonautoimmune urticaria","volume":"127","author":"Ferrer","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4168\/aair.2012.4.6.357","article-title":"Effects of omalizumab treatment in patients with refractory chronic urticaria","volume":"4","author":"Nam","year":"2012","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaci.2017.06.032_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaci.2014.04.036","article-title":"The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria","volume":"135","author":"Chang","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0091-6749(78)90113-6","article-title":"Assessment of tissue fluid histamine levels in patients with urticaria","volume":"61","author":"Kaplan","year":"1978","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib25","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/0091-6749(92)90297-F","article-title":"Chronic idiopathic urticaria: profiles of skin mast cell histamine release during active disease and remission","volume":"89","author":"Jacques","year":"1992","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib26","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jaci.2016.08.050","article-title":"Autoimmune chronic spontaneous urticaria: what we know and what we don't know","volume":"139","author":"Kolkhir","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000336572","article-title":"Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction","volume":"224","author":"Kring Tannert","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.jaci.2017.06.032_bib28","doi-asserted-by":"crossref","first-page":"e14794","DOI":"10.1371\/journal.pone.0014794","article-title":"IgE mediated autoallergy against thyroid peroxidase\u2014a novel pathomechanism of chronic spontaneous urticaria?","volume":"6","author":"Altrichter","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2017.06.032_bib29","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00403-012-1236-2","article-title":"Histamine release-neutralization assay for sera of patients with atopic dermatitis and\/or cholinergic urticaria is useful to screen type I hypersensitivity against sweat antigens","volume":"304","author":"Shindo","year":"2012","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2017.06.032_bib30","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1365-2133.1987.tb04898.x","article-title":"Symptomatic dermographism (factitious urticaria)\u2014passive transfer experiments from human to monkey","volume":"116","author":"Murphy","year":"1987","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.06.032_bib31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/0002-9343(73)90221-0","article-title":"Dermographia mediated by immunoglobulin E","volume":"54","author":"Newcomb","year":"1973","journal-title":"Am J Med"},{"key":"10.1016\/j.jaci.2017.06.032_bib32","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1056\/NEJM198110293051808","article-title":"Idiopathic cold urticaria: in\u00a0vitro demonstration of histamine release upon challenge of skin biopsies","volume":"305","author":"Kaplan","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.06.032_bib33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/1523-1747.ep12462239","article-title":"Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes","volume":"90","author":"Gruber","year":"1988","journal-title":"J Invest Dermatol"},{"issue":"suppl\u00a02","key":"10.1016\/j.jaci.2017.06.032_bib34","first-page":"153","article-title":"Allergic hypersensitivity skin reactions following sun exposure","volume":"32","author":"Lugovic Mihic","year":"2008","journal-title":"Coll Antropol"},{"key":"10.1016\/j.jaci.2017.06.032_bib35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1185\/030079903125002171","article-title":"Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma","volume":"19","author":"Hochhaus","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaci.2017.06.032_bib36","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaad.2015.11.021","article-title":"Omalizumab in patients with severe and refractory solar urticaria: A\u00a0phase II multicentric study","volume":"74","author":"Aubin","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.06.032_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.01.043","article-title":"Omalizumab is effective in cold urticaria\u2014results of a randomized, placebo controlled trial","author":"Metz","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.01.042","article-title":"Omalizumab is effective in symptomatic dermographism\u2014results of a randomized, placebo controlled trial","author":"Maurer","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdermsci.2013.08.011","article-title":"Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis","volume":"73","author":"Metz","year":"2014","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2017.06.032_bib40","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjd.14540","article-title":"Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients","volume":"175","author":"Ghazanfar","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.06.032_bib41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000320233","article-title":"Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria","volume":"154","author":"Metz","year":"2011","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib42","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamadermatol.2013.8705","article-title":"Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria","volume":"150","author":"Metz","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2017.06.032_bib43","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/j.1398-9995.2010.02409.x","article-title":"Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy","volume":"65","author":"Krause","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.06.032_bib44","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/bjd.12628","article-title":"Effects of omalizumab in a patient with three types of chronic urticaria","volume":"170","author":"Vieira Dos Santos","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.06.032_bib45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000346284","article-title":"Treatment of severe cold contact urticaria with omalizumab: case reports","volume":"4","author":"Brodska","year":"2012","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaci.2017.06.032_bib46","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/pai.12609","article-title":"Omalizumab in pediatric cold contact urticaria: warm blanket for a cold bath?","volume":"27","author":"Kitsioulis","year":"2016","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib47","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.anai.2013.12.005","article-title":"Real-life experiences with omalizumab for the treatment of chronic urticaria","volume":"112","author":"Sussman","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib48","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jaad.2012.10.026","article-title":"Effective treatment of idiopathic chronic cold urticaria with omalizumab: report of 3 cases","volume":"69","author":"Le Moing","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.06.032_bib49","first-page":"303","article-title":"Treatment of severe cold-induced urticaria in a child with omalizumab","volume":"25","author":"Alba Marin","year":"2015","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib50","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2340\/00015555-2224","article-title":"Bullous delayed pressure urticaria responding to omalizumab","volume":"96","author":"Muller","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2017.06.032_bib51","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1398-9995.2009.02188.x","article-title":"Efficacy of omalizumab in delayed pressure urticaria: a case report","volume":"65","author":"Bindslev-Jensen","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.06.032_bib52","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaip.2016.07.016","article-title":"Rapid response to omalizumab in 3 cases of delayed pressure urticaria","volume":"5","author":"Quintero","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2017.06.032_bib53","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/pai.12407","article-title":"Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series","volume":"26","author":"Netchiporouk","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib54","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.anai.2015.10.009","article-title":"Successful treatment of occupational delayed pressure urticaria and angioedema with omalizumab","volume":"116","author":"Geller","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib55","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.aller.2012.11.001","article-title":"Successful treatment of severe delayed pressure angio-oedema with omalizumab","volume":"42","author":"Rodriguez-Rodriguez","year":"2014","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.jaci.2017.06.032_bib56","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/0394632015623795","article-title":"Effective treatment of different phenotypes of chronic urticaria with omalizumab: case reports and review of literature","volume":"29","author":"Kasperska-Zajac","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jaci.2017.06.032_bib57","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s00105-016-3913-0","article-title":"[Partial response of solar urticaria to omalizumab therapy]","volume":"68","author":"Kowalzick","year":"2017","journal-title":"Hautarzt"},{"key":"10.1016\/j.jaci.2017.06.032_bib58","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaci.2009.11.007","article-title":"Partial improvement of solar urticaria after omalizumab","volume":"125","author":"Waibel","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib59","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-0781.2011.00624.x","article-title":"Failure of omalizumab (Xolair(R)) in the treatment of a case of solar urticaria caused by ultraviolet A\u00a0and visible light","volume":"27","author":"Duchini","year":"2011","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaci.2017.06.032_bib60","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/jdv.12922","article-title":"Failure of omalizumab in the treatment of solar urticaria","volume":"30","author":"Muller","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2017.06.032_bib61","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/pai.12413","article-title":"Treatment with omalizumab in a 16-year-old Caucasian girl with refractory solar urticaria","volume":"26","author":"Arasi","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib62","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/jdv.13001","article-title":"Three cases of solar urticaria successfully treated with omalizumab","volume":"30","author":"Baliu-Pique","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2017.06.032_bib63","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ad.2016.11.015","article-title":"Refractory solar urticaria successfully treated with omalizumab with normalization of phototest","volume":"108","author":"Combalia","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.jaci.2017.06.032_bib64","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.anai.2015.12.023","article-title":"Effectiveness of omalizumab in severe solar urticaria","volume":"116","author":"de Dios-Velazquez","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib65","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/j.1398-9995.2008.01879.x","article-title":"Successful treatment of solar urticaria with anti-immunoglobulin E therapy","volume":"63","author":"Guzelbey","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.06.032_bib66","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/phpp.12271","article-title":"Visible light-induced solar urticaria is improved by omalizumab","volume":"32","author":"Moncourier","year":"2016","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaci.2017.06.032_bib67","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/ced.12951","article-title":"Solar urticaria induced by visible light: successful treatment with omalizumab","volume":"41","author":"Terrani","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2017.06.032_bib68","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/ddg.13017","article-title":"Successful treatment of solar urticaria with omalizumab","volume":"14","author":"Bruning","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaci.2017.06.032_bib69","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/pai.12441","article-title":"Successful omalizumab treatment of severe solar urticaria in a 6-year-old child","volume":"26","author":"Levi","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib70","first-page":"519","article-title":"Omalizumab treatment in 2 cases of refractory heat urticaria","volume":"23","author":"Carballada","year":"2013","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib71","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2230.2012.04430.x","article-title":"Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema","volume":"38","author":"Pressler","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2017.06.032_bib72","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1398-9995.2007.01591.x","article-title":"Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy","volume":"63","author":"Metz","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.06.032_bib73","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2500\/aap.2009.30.3237","article-title":"A case of severe refractory chronic urticaria: a novel method for evaluation and treatment","volume":"30","author":"Otto","year":"2009","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2017.06.032_bib74","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1111\/j.1365-2230.2009.03748.x","article-title":"Failure of omalizumab in cholinergic urticaria","volume":"35","author":"Sabroe","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2017.06.032_bib75","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.4103\/0366-6999.157703","article-title":"Healing effects of omalizumab in a patient with cholinergic urticaria associated severe dyspeptic complaints","volume":"128","author":"Kutlu","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jaci.2017.06.032_bib76","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaip.2015.12.017","article-title":"A case of aquagenic urticaria successfully treated with omalizumab","volume":"4","author":"Rorie","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2017.06.032_bib77","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2230.2007.02376.x","article-title":"Acquired cold urticaria: clinical picture and update on diagnosis and treatment","volume":"32","author":"Siebenhaar","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2017.06.032_bib78","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1398-9995.1997.tb02593.x","article-title":"Physical urticaria: classification and diagnostic guidelines. An EAACI position paper","volume":"52","author":"Kontou-Fili","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.06.032_bib79","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2340\/00015555-0306","article-title":"Urticarial dermographism: clinical features and response to psychosocial stress","volume":"87","author":"Wallengren","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2017.06.032_bib80","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/jdv.12661","article-title":"Symptomatic dermographism: an inadequately described disease","volume":"29","author":"Schoepke","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2017.06.032_bib81","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/j.ijcard.2014.07.040","article-title":"Kounis syndrome following cold urticaria: the swimmer's death","volume":"176","author":"Mazarakis","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jaci.2017.06.032_bib82","first-page":"1219","article-title":"[Cold urticaria and swimmer's death]","volume":"46","author":"Brandes","year":"1970","journal-title":"Z Allgemeinmed"},{"key":"10.1016\/j.jaci.2017.06.032_bib83","first-page":"497","article-title":"[Drowning and urticaria caused by cold]","volume":"37","author":"Delore","year":"1956","journal-title":"J Med Lyon"},{"key":"10.1016\/j.jaci.2017.06.032_bib84","first-page":"609","article-title":"Essential cold urticaria. A\u00a0potential cause of death while swimming","volume":"91","author":"Sigal","year":"1964","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.jaci.2017.06.032_bib85","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0190-9622(93)70273-V","article-title":"Diagnosis and incidence of delayed pressure urticaria in patients with chronic urticaria","volume":"29","author":"Barlow","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.06.032_bib86","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1046\/j.1365-2133.1999.02767.x","article-title":"The extent and nature\u00a0of\u00a0disability in different urticarial conditions","volume":"140","author":"Poon","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.06.032_bib87","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jaad.2008.08.020","article-title":"Solar urticaria","volume":"59","author":"Botto","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.06.032_bib88","unstructured":"British Association of Dermatologists. Solar urticaria patient information leaflet. 2016. Available from: http:\/\/www.bad.org.uk\/shared\/get-file.ashx?id=129&itemtype=document. Accessed August 14, 2017."},{"key":"10.1016\/j.jaci.2017.06.032_bib89","series-title":"Fitzpatrick's Dermatology","article-title":"Solar urticaria","author":"Maurer","year":"2017"},{"key":"10.1016\/j.jaci.2017.06.032_bib90","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1398-9995.2009.02179.x","article-title":"EAACI\/GA2LEN\/EDF\/WAO guideline: definition, classification and diagnosis of urticaria","volume":"64","author":"Zuberbier","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.06.032_bib91","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2340\/00015555-0240","article-title":"Urticaria: current opinions about etiology, diagnosis and therapy","volume":"87","author":"Zuberbier","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2017.06.032_bib92","first-page":"552","article-title":"Immediate contact skin reactions, an update of contact urticaria, contact urticaria syndrome and protein contact dermatitis\u2014\u201ca never ending story.\u201d","volume":"20","author":"Gimenez-Arnau","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaci.2017.06.032_bib93","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaci.2016.07.047","article-title":"Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria","volume":"139","author":"Gericke","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.06.032_bib94","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jaip.2015.04.015","article-title":"Similar efficacy with omalizumab in chronic idiopathic\/spontaneous urticaria despite different background therapy","volume":"3","author":"Casale","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2017.06.032_bib95","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/j.jaci.2016.06.023","article-title":"A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria","volume":"138","author":"Harris","year":"2016","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917311636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917311636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:10:11Z","timestamp":1758791411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674917311636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0091674917311636"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2017.06.032","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727847955.793543504","asserted-by":"object"}]},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab treatment in patients with chronic inducible urticaria: A\u00a0systematic review of published evidence","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2017.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}